<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02022007</url>
  </required_header>
  <id_info>
    <org_study_id>RP13-013</org_study_id>
    <secondary_id>BMS CV181-354</secondary_id>
    <nct_id>NCT02022007</nct_id>
  </id_info>
  <brief_title>Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis</brief_title>
  <acronym>BMS-AZPCOS</acronym>
  <official_title>Metabolic and Endocrine Effects of Combination of Metformin and DPP-4 Inhibitor Saxagliptin Compared to Saxagliptin or Metformin XR Monotherapy in Patients With PCOS and Impaired Glucose Regulation: A Single-blinded Randomized Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Woman's</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Woman's</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the present proposal is to compare the clinical, endocrine and metabolic
      effects of therapy with combination saxagliptin and metformin to saxagliptin and metformin
      monotherapy in women with PCOS and prediabetic hyperglycemia (IFG, IGT or IFG/IGT).
      Saxagliptin is an oral dipeptidyl peptidase IV (DPP-4) inhibitor whose mechanism of action is
      to prolong the duration of blood glucagon-like peptide (GLP-1) and glucose-dependent
      insulinotropic polypeptide (GIP) levels by inhibiting their degradation and thereby
      augmenting insulin secretion. This study will serve as a pilot investigation to open
      perspectives for future studies to explore the potential of combining anti-diabetic drugs
      with different mechanisms of action in in patients with PCOS and impaired glucose regulation
      (IGR), especially ones for whom standard treatment with metformin is less effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A major change in the treatment of polycystic ovary syndrome (PCOS) was initiated by the
      understanding that many women with this disorder compensate insulin resistance with a period
      of hypersecretion of insulin by the pancreatic ß-cell. In addition, women with PCOS have
      significantly higher basal insulin secretory rates, reduced insulin clearance rates, and
      attenuated secretory responses to meals. The decreased postprandial response in these
      patients resembles the ß-cell dysfunction of type 2 diabetes (DM2) and may account for the
      increased incidence of impaired glucose tolerance in this population. Current research has
      shown that the use of diabetes management practices aimed at reducing insulin resistance and
      hyperinsulinemia (such as weight reduction and the administration of oral antidiabetic drugs)
      in women with PCOS can not only improve glucose and lipid metabolism but can also reverse
      testosterone abnormalities and restore menstrual cycles.

      The optimal modality for long-term treatment of PCOS should positively influence androgen
      synthesis, sex hormone binding globulin (SHBG) production, the lipid profile, insulin
      sensitivity, and clinical symptoms including hirsutism and irregular menstrual cycles.
      Improvement of insulin sensitivity may reverse some of the demand on the ß-cell and promote
      improvement in glucose tolerance. However, while insulin resistance plays a key role in the
      predisposition to diabetes in PCOS; defects in insulin secretion also appear to contribute to
      its development. Preferably therapy for women with PCOS should also produce no weight gain,
      hypoglycemia, or other limiting or unmanageable side effects as well as preserve or enhance
      ß-cell function.

      Presently, in the literature, there are described new, more efficient methods of diabetes
      prevention in groups with a high risk of this disorder, which involve both, lifestyle
      modification and pharmacological therapies. Lifestyle intervention was found to reduce the
      incidence of type 2 diabetes by 58% and metformin by 31% as compared with placebo. The use of
      rosiglitazone in subjects with prediabetes resulted in a 60% reduction of the diabetes
      incidence rate. Whether pharmacological therapy should be prescribed for diabetes prevention
      is an open question given that waiting to add drug therapy until diabetes develops can arrest
      β-cell decline, albeit at a lower level of β-cell function than when medications are used for
      prevention. Studies are needed for optimal postpartum and long-term health of women who have
      had gestational diabetes (GDM). Considerable recent evidence suggests that incretin-based
      therapies may be useful for the prevention of DM2. Whereas native GLP-1 has a very short
      half-life, continuous infusion of GLP-1 improves first and second-phase insulin secretion
      suggesting that early GLP-1 therapy may preserve ß-cell function in subjects with IGT or mild
      DM2. Incretin mimetics and inhibitors of the protease dipeptidyl peptidase (DPP)-4 use the
      anti-diabetic properties of the incretin hormone, glucagon-like peptide (GLP)-1 hormone to
      augment glucose-induced insulin secretion in a highly glucose-dependent manner, thus
      preventing GLP-1 alone from provoking hypoglycemia. Additional beneficial effects of GLP-1 on
      endocrine pancreatic islets are that it 1) supports the synthesis of proinsulin to replenish
      insulin stores in β-cells; 2) reduces the rate of β-cell apoptosis when islets are incubated
      in a toxic environment (glucotoxicity, lipotoxicity, cytotoxic cytokines); and 3) promotes
      differentiation of precursor cells with the ability to develop into β-cells and proliferation
      of β-cell lines, and in whole animals (rodent studies), this leads to an increased β-cell
      mass within a few days or weeks. Furthermore, GLP-1 can lower glucagon concentrations, i.e.,
      induce α-cells to respond again to the inhibitory action of hyperglycemia, while leaving the
      counterregulatory glucagon responses undisturbed, as in the case of hypoglycemia. Additional
      activities of GLP-1 are the deceleration of gastric emptying, which slows the entry of
      nutrients into the circulation after meals, a reduction in appetite, and earlier induction of
      satiety, leading to weight reduction with chronic exposure. Inhibition of DPP-4 increases the
      concentration of GLP-1 and may potentially delay disease progression in prediabetes
      considering the β-cell function improvement in DM2 and β-cell mass shown to increase in
      animal models. The objective of the present proposal is to compare the clinical, endocrine
      and metabolic effects of therapy with combination saxagliptin and metformin to saxagliptin
      and metformin monotherapy in women with PCOS and prediabetic hyperglycemia (IFG, IGT or
      IFG/IGT). Since aberrant first-phase insulin secretion and impaired suppression of endogenous
      glucose production are major contributors to postprandial hyperglycemia and development of
      DM2, the effects of saxagliptin to target these defects, and normalize glucose excursions are
      likely to be clinically significant in patients with PCOS and impaired glucose regulation.
      This study will evaluate the impact of treatment with combination of metformin and
      saxagliptin (Kombiglyze XR) compared to saxagliptin (Onglyza) or metformin XR (Glucophage XR)
      monotherapy over a 16-week period on glycemia and insulin action (fasting, 2 hour, and mean
      stimulated glucose levels, insulin sensitivity and secretion), hyperandrogenism (total T,
      DHEAS, SHBG and calculated free androgen index [FAI]), cardiometabolic markers (lipid
      profile, blood pressure), and anthropometric measurements (BMI, waist: hip ratio, absolute
      weight) in patients with PCOS and prediabetic hyperglycemia
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose Metabolism</measure>
    <time_frame>16 weeks</time_frame>
    <description>Glucose metabolic secretory status after drug treatment (normal, impaired or diabetic). We used the American Diabetes Association (ADA) definition of impairment which is fasting glucose greater than 100 mg/dL and/or 2 hour glucose greater than 140 mg/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral Disposition Index</measure>
    <time_frame>16 weeks</time_frame>
    <description>Post-treatment in insulin-sensitivity-secretion index . The insulin secretion-sensitivity index (IS-SI) provides an estimate of β-cell compensation relative to the prevailing insulin resistance, not absolute insulin secretion. It is derived by applying the concept of the disposition index (DI) to measurements obtained during the 2-h OGTT. The IS-SI, a surrogate measure of the DI derived from the OGTT (IGI multiplied by the SIOGTT], was calculated as the product of acute β-cell response [IGI] and Matsuda index (SIOGTT) based on the existence of the predicted hyperbolic relationship between these two measures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Glucose</measure>
    <time_frame>16 weeks</time_frame>
    <description>Post-treatment fasting glucose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Blood Glucose During the OGTT</measure>
    <time_frame>16 weeks</time_frame>
    <description>Post-treatment mean blood glucose levels. Mean blood glucose (MBG) concentrations were calculated by summing glucose values obtained at 0,30,60 and 120 minutes during the OGTT and dividing by 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matsuda Index of Insulin-Sensitivity (SI OGTT)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Post-treatment insulin sensitivity index. The Matsuda index of whole-body insulin sensitivity is calculated from an oral glucose tolerance test (10,000/square root of [fasting glucose x fasting insulin] x [mean glucose x mean insulin during OGTT]), and is highly correlated with the rate of whole-body glucose disposal during the euglycemic insulin clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pancreatic ß-cell Compensatory Function</measure>
    <time_frame>16 weeks</time_frame>
    <description>Post-treatment corrected early phase insulin secretion index (IGI/HOMA-IR). . Early pancreatic β-cell response is estimated as the insulinogenic index (IGI) derived from the ratio of the increment of insulin to that of glucose 30 minutes after a glucose load (insulin 30 min − insulin 0 min/glucose 30 min − glucose 0 min) corrected for by the relative level of insulin resistance (IGI/HOMA-IR which is estimated by homeostasis model assessment of insulin resistance using fasting insulin and glucose levels).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index at 16 Weeks</measure>
    <time_frame>16 weeks</time_frame>
    <description>Height and weight measurements were used to calculate body mass index (BMI), defined as kg/m2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference at 16 Weeks</measure>
    <time_frame>16 weeks</time_frame>
    <description>The circumference measurement was taken in the upright position using a 15-mm width flexible metric tape held close to the body but not tight enough to indent the skin. Waist circumference (WC) was measured in centimeters at the narrowest level midway between the lowest ribs and the iliac crest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menstrual Cycle Interval at 16 Weeks</measure>
    <time_frame>16 weeks</time_frame>
    <description>The number of menstrual cycles during the previous year was recorded and the average menstrual interval calculated by dividing 365 by the number of menstrual cycles in the previous year . During the study period, the patients in a menstrual diary recorded vaginal bleeding over 16 weeks. The effects of treatment intervention on menstrual cycle interval was calculated evaluated by dividing 112 days by the number of menstrual cycles recorded in each patient's menstrual cycle diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride (TRG) /HDL-cholesterol Ratio</measure>
    <time_frame>16 weeks</time_frame>
    <description>The measure of TRG levels and HDL- cholesterol levels are used as an estimate of insulin sensitivity. A TRG/HDL-C ratio of greater than 3.0 is used as an indirect measure of insulin resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free Androgen Index (FAI)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Hyperandrogenism is measured by a combination of total testosterone (T) and sex hormone binding globulin (SHBG). The FAI was calculated as the quotient 100 x T/SHBG; hyperandrogenism was defined by a FAI value &gt;3.85.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With No Clinically Significant Changes in Liver Enzyme Levels or Positive Pregnancy Tests</measure>
    <time_frame>16 weeks</time_frame>
    <description>The safety criteria will include laboratory values for liver enzymes and document the absence of pregnancy in all participants during the trial</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Disorder of Glucose Regulation</condition>
  <arm_group>
    <arm_group_label>Metformin XR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 2000 mg daily (QD) for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Saxagliptin 5 mg QD for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saxagliptin-Metformin XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saxagliptin-Metformin XR (combination pill)
5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin XR</intervention_name>
    <description>Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks
Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study</description>
    <arm_group_label>Metformin XR</arm_group_label>
    <other_name>Glucophage XR</other_name>
    <other_name>Biguanide-insulin sensitizer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>Start 1 pill (5 mg)) for 3 weeks
Remain at 1 pill (5mg dose) for remainder of study</description>
    <arm_group_label>Saxagliptin</arm_group_label>
    <other_name>Onglyza</other_name>
    <other_name>DPP-4 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin-Metformin XR</intervention_name>
    <description>Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks
Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study</description>
    <arm_group_label>Saxagliptin-Metformin XR</arm_group_label>
    <other_name>Kombiglyze XR</other_name>
    <other_name>Combination DPP-4 inhibitor and Glucophage XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females 18 years to 42 years of age with polycystic ovary syndrome(NIH PCOS criteria)
             with prediabetic hyperglycemia determined by an 75 gram oral glucose tolerance test
             (OGTT). Study subjects will be inclusive of PCOS women with impaired fasting glucose
             (IFG), impaired glucose tolerance (IGT), or both (IFG/IGT).

          -  Written consent for participation in the study

        Exclusion Criteria:

          -  Presence of significant systemic disease, heart problems including congestive heart
             failure, history of pancreatitis, or diabetes mellitus (Type 1 or 2)

          -  Any hepatic diseases in the past (viral hepatitis, toxic hepatic damage, jaundice of
             unknown etiology), gallstones, abnormal liver function tests or renal impairment
             (elevated serum creatinine levels or abnormal creatinine clearance)

          -  Uncontrolled thyroid disease (documented normal TSH), Cushing's syndrome, congenital
             adrenal hyperplasia or hyperprolactinemia

          -  Significantly elevated triglyceride levels (fasting triglyceride &gt; 400 mg %)

          -  Untreated or poorly controlled hypertension (sitting blood pressure &gt; 160/95 mm Hg)

          -  Use of hormonal medications, drugs known to affect gastrointestinal motility,
             lipid-lowering (statins, etc.) and/or anti-obesity drugs or medications that interfere
             with carbohydrate metabolism (such as isotretinoin, hormonal contraceptives,
             gonadotropin releasing hormone (GnRH) analogues, glucocorticoids, anabolic steroids,
             C-19 progestins) for at least 8 weeks. Use of anti-androgens that act peripherally to
             reduce hirsutism such as 5-alpha reductase inhibitors (finasteride, spironolactone,
             flutamide) for at least 4 weeks

          -  Prior history of a malignant disease requiring chemotherapy

          -  Known hypersensitivity or contraindications to use of insulin sensitizers such as
             metformin or thiazolidinediones

          -  History of hypersensitivity reaction to saxagliptin or other DPP-4 inhibitors (e.g.
             anaphylaxis, angioedema, exfoliative skin conditions)

          -  Current use of metformin, thiazolidinediones, glucagon-like peptide -1 receptor
             agonists, DPP-4 inhibitors, or weight loss medications (prescription or OTC) Patients
             must stop use of insulin sensitizers or antidiabetic medicines such as metformin for
             at least 4 weeks or thiazolidinediones, GLP1 agonists or DPPIV inhibitors for 8 weeks.

          -  Prior use of medication to treat diabetes except gestational diabetes

          -  Use of drugs known to exacerbate glucose tolerance

          -  Eating disorders (anorexia, bulimia) or gastrointestinal disorders

          -  Suspected pregnancy (documented negative serum pregnancy test), desiring pregnancy
             during the study treatment interval, breastfeeding, or known pregnancy in last 2
             months

          -  Active or prior history of substance abuse (smoke or tobacco use within past 3 years)
             or significant intake of alcohol or history of alcoholism

          -  Patient not willing to use adequate barrier contraception during study period (unless
             sterilized or have an IUD).

          -  Debilitating psychiatric disorder such as psychosis or neurological condition that
             might confound outcome variables

          -  Inability or refusal to comply with protocol

          -  Not currently participating or having participated in an experimental drug study in
             previous three months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Elkind-Hirsch, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Woman's Hospital, Louisiana</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woman's Hospital</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2013</study_first_submitted>
  <study_first_submitted_qc>December 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2013</study_first_posted>
  <results_first_submitted>November 9, 2016</results_first_submitted>
  <results_first_submitted_qc>May 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 28, 2017</results_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Woman's</investigator_affiliation>
    <investigator_full_name>Karen Elkind-Hirsch</investigator_full_name>
    <investigator_title>Director of Research</investigator_title>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>IGT</keyword>
  <keyword>DPP-4 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>PCOS women age 18 and 42 years and impaired glucose regulation were enrolled in the study from March 2014 to January 2016. PCOS was defined according to modified National Institutes of Health [NIH] 1990 criteria. ). Prediabetic hyperglycemia was determined by a 75-gram OGTT and included impaired fasting glucose (IFG), IGT, or both (IFG/IGT).</recruitment_details>
      <pre_assignment_details>Exclusion criteria included diabetic subjects, smokers, suspected pregnancy, desiring pregnancy or injectable hormonal contraceptive use within 6 months; and use of oral contraceptives, other steroid hormones, drugs that affect gastrointestinal motility or carbohydrate metabolism and/or anti-obesity drugs within 3 months prior to study entry.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Metformin XR</title>
          <description>Metformin 2000 mg QD for 16 weeks
Metformin XR: Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks
Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study</description>
        </group>
        <group group_id="P2">
          <title>Saxagliptin</title>
          <description>Saxagliptin 5 mg QD for 16 weeks
Saxagliptin: Start 1 pill (5 mg)) for 3 weeks
Remain at 1 pill (5mg dose) for remainder of study</description>
        </group>
        <group group_id="P3">
          <title>Saxagliptin-Metformin XR</title>
          <description>Saxagliptin-Metformin XR (combination pill)
5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks
Saxagliptin-Metformin XR: Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks
Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants had PCOS and were glucose impaired</population>
      <group_list>
        <group group_id="B1">
          <title>Metformin XR</title>
          <description>Metformin 2000 mg QD for 16 weeks
Metformin XR: Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks
Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study</description>
        </group>
        <group group_id="B2">
          <title>Saxagliptin</title>
          <description>Saxagliptin 5 mg QD for 16 weeks
Saxagliptin: Start 1 pill (5 mg)) for 3 weeks
Remain at 1 pill (5mg dose) for remainder of study</description>
        </group>
        <group group_id="B3">
          <title>Saxagliptin-Metformin XR</title>
          <description>Saxagliptin-Metformin XR (combination pill)
5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks
Saxagliptin-Metformin XR: Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks
Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>All participants had to be 18 to 42 years to participate</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>All participants had to be female to qualify</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Our patient population is approximately 64% Caucasian and 35% African -American. The remaining ethnicities comprise about 1%.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>All participants were from Baton Rouge and surrounding parishes</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glucose Metabolism</title>
        <description>Glucose metabolic secretory status after drug treatment (normal, impaired or diabetic). We used the American Diabetes Association (ADA) definition of impairment which is fasting glucose greater than 100 mg/dL and/or 2 hour glucose greater than 140 mg/dL.</description>
        <time_frame>16 weeks</time_frame>
        <population>Change from impaired to normal was evaluated. No patients were diabetic at the start or completion of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR</title>
            <description>Metformin 2000 mg QD for 16 weeks
Metformin XR: Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks
Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin 5 mg QD for 16 weeks
Saxagliptin: Start 1 pill (5 mg)) for 3 weeks
Remain at 1 pill (5mg dose) for remainder of study</description>
          </group>
          <group group_id="O3">
            <title>Saxagliptin-Metformin XR</title>
            <description>Saxagliptin-Metformin XR (combination pill)
5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks
Saxagliptin-Metformin XR: Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks
Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Metabolism</title>
          <description>Glucose metabolic secretory status after drug treatment (normal, impaired or diabetic). We used the American Diabetes Association (ADA) definition of impairment which is fasting glucose greater than 100 mg/dL and/or 2 hour glucose greater than 140 mg/dL.</description>
          <population>Change from impaired to normal was evaluated. No patients were diabetic at the start or completion of the study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Study change from dysglycemia to normal glucose state</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.007</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oral Disposition Index</title>
        <description>Post-treatment in insulin-sensitivity-secretion index . The insulin secretion-sensitivity index (IS-SI) provides an estimate of β-cell compensation relative to the prevailing insulin resistance, not absolute insulin secretion. It is derived by applying the concept of the disposition index (DI) to measurements obtained during the 2-h OGTT. The IS-SI, a surrogate measure of the DI derived from the OGTT (IGI multiplied by the SIOGTT], was calculated as the product of acute β-cell response [IGI] and Matsuda index (SIOGTT) based on the existence of the predicted hyperbolic relationship between these two measures</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR</title>
            <description>Metformin 2000 mg QD for 16 weeks
Metformin XR: Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks
Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin 5 mg QD for 16 weeks
Saxagliptin: Start 1 pill (5 mg)) for 3 weeks
Remain at 1 pill (5mg dose) for remainder of study</description>
          </group>
          <group group_id="O3">
            <title>Saxagliptin-Metformin XR</title>
            <description>Saxagliptin-Metformin XR (combination pill)
5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks
Saxagliptin-Metformin XR: Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks
Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Disposition Index</title>
          <description>Post-treatment in insulin-sensitivity-secretion index . The insulin secretion-sensitivity index (IS-SI) provides an estimate of β-cell compensation relative to the prevailing insulin resistance, not absolute insulin secretion. It is derived by applying the concept of the disposition index (DI) to measurements obtained during the 2-h OGTT. The IS-SI, a surrogate measure of the DI derived from the OGTT (IGI multiplied by the SIOGTT], was calculated as the product of acute β-cell response [IGI] and Matsuda index (SIOGTT) based on the existence of the predicted hyperbolic relationship between these two measures</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208" spread="126"/>
                    <measurement group_id="O2" value="359" spread="295"/>
                    <measurement group_id="O3" value="532" spread="347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This was a Subjects (SS)/Groups repeated measures design</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.02</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Glucose</title>
        <description>Post-treatment fasting glucose levels</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR</title>
            <description>Metformin 2000 mg QD for 16 weeks
Metformin XR: Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks
Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin 5 mg QD for 16 weeks
Saxagliptin: Start 1 pill (5 mg)) for 3 weeks
Remain at 1 pill (5mg dose) for remainder of study</description>
          </group>
          <group group_id="O3">
            <title>Saxagliptin-Metformin XR</title>
            <description>Saxagliptin-Metformin XR (combination pill)
5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks
Saxagliptin-Metformin XR: Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks
Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Glucose</title>
          <description>Post-treatment fasting glucose levels</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="0.7"/>
                    <measurement group_id="O2" value="5.3" spread=".51"/>
                    <measurement group_id="O3" value="5.0" spread=".36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pretreatment fasting glucose levels were compared with post-treatment levels</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>n</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Blood Glucose During the OGTT</title>
        <description>Post-treatment mean blood glucose levels. Mean blood glucose (MBG) concentrations were calculated by summing glucose values obtained at 0,30,60 and 120 minutes during the OGTT and dividing by 4.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR</title>
            <description>Metformin 2000 mg QD for 16 weeks
Metformin XR: Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks
Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin 5 mg QD for 16 weeks
Saxagliptin: Start 1 pill (5 mg)) for 3 weeks
Remain at 1 pill (5mg dose) for remainder of study</description>
          </group>
          <group group_id="O3">
            <title>Saxagliptin-Metformin XR</title>
            <description>Saxagliptin-Metformin XR (combination pill)
5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks
Saxagliptin-Metformin XR: Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks
Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Glucose During the OGTT</title>
          <description>Post-treatment mean blood glucose levels. Mean blood glucose (MBG) concentrations were calculated by summing glucose values obtained at 0,30,60 and 120 minutes during the OGTT and dividing by 4.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="1.4"/>
                    <measurement group_id="O2" value="7.1" spread="1.64"/>
                    <measurement group_id="O3" value="6.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.038</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Matsuda Index of Insulin-Sensitivity (SI OGTT)</title>
        <description>Post-treatment insulin sensitivity index. The Matsuda index of whole-body insulin sensitivity is calculated from an oral glucose tolerance test (10,000/square root of [fasting glucose x fasting insulin] x [mean glucose x mean insulin during OGTT]), and is highly correlated with the rate of whole-body glucose disposal during the euglycemic insulin clamp</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR</title>
            <description>Metformin 2000 mg QD for 16 weeks
Metformin XR: Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks
Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin 5 mg QD for 16 weeks
Saxagliptin: Start 1 pill (5 mg)) for 3 weeks
Remain at 1 pill (5mg dose) for remainder of study</description>
          </group>
          <group group_id="O3">
            <title>Saxagliptin-Metformin XR</title>
            <description>Saxagliptin-Metformin XR (combination pill)
5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks
Saxagliptin-Metformin XR: Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks
Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study</description>
          </group>
        </group_list>
        <measure>
          <title>Matsuda Index of Insulin-Sensitivity (SI OGTT)</title>
          <description>Post-treatment insulin sensitivity index. The Matsuda index of whole-body insulin sensitivity is calculated from an oral glucose tolerance test (10,000/square root of [fasting glucose x fasting insulin] x [mean glucose x mean insulin during OGTT]), and is highly correlated with the rate of whole-body glucose disposal during the euglycemic insulin clamp</description>
          <units>Index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.6"/>
                    <measurement group_id="O2" value="3.5" spread="3.4"/>
                    <measurement group_id="O3" value="4.1" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pancreatic ß-cell Compensatory Function</title>
        <description>Post-treatment corrected early phase insulin secretion index (IGI/HOMA-IR). . Early pancreatic β-cell response is estimated as the insulinogenic index (IGI) derived from the ratio of the increment of insulin to that of glucose 30 minutes after a glucose load (insulin 30 min − insulin 0 min/glucose 30 min − glucose 0 min) corrected for by the relative level of insulin resistance (IGI/HOMA-IR which is estimated by homeostasis model assessment of insulin resistance using fasting insulin and glucose levels).</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR</title>
            <description>Metformin 2000 mg QD for 16 weeks
Metformin XR: Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks
Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin 5 mg QD for 16 weeks
Saxagliptin: Start 1 pill (5 mg)) for 3 weeks
Remain at 1 pill (5mg dose) for remainder of study</description>
          </group>
          <group group_id="O3">
            <title>Saxagliptin-Metformin XR</title>
            <description>Saxagliptin-Metformin XR (combination pill)
5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks
Saxagliptin-Metformin XR: Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks
Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study</description>
          </group>
        </group_list>
        <measure>
          <title>Pancreatic ß-cell Compensatory Function</title>
          <description>Post-treatment corrected early phase insulin secretion index (IGI/HOMA-IR). . Early pancreatic β-cell response is estimated as the insulinogenic index (IGI) derived from the ratio of the increment of insulin to that of glucose 30 minutes after a glucose load (insulin 30 min − insulin 0 min/glucose 30 min − glucose 0 min) corrected for by the relative level of insulin resistance (IGI/HOMA-IR which is estimated by homeostasis model assessment of insulin resistance using fasting insulin and glucose levels).</description>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.3"/>
                    <measurement group_id="O2" value="1.4" spread="1.7"/>
                    <measurement group_id="O3" value="1.03" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.025</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index at 16 Weeks</title>
        <description>Height and weight measurements were used to calculate body mass index (BMI), defined as kg/m2.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR</title>
            <description>Metformin 2000 mg QD for 16 weeks
Metformin XR: Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks
Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin 5 mg QD for 16 weeks
Saxagliptin: Start 1 pill (5 mg)) for 3 weeks
Remain at 1 pill (5mg dose) for remainder of study</description>
          </group>
          <group group_id="O3">
            <title>Saxagliptin-Metformin XR</title>
            <description>Saxagliptin-Metformin XR (combination pill)
5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks
Saxagliptin-Metformin XR: Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks
Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index at 16 Weeks</title>
          <description>Height and weight measurements were used to calculate body mass index (BMI), defined as kg/m2.</description>
          <units>kg/mg2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" spread="7.7"/>
                    <measurement group_id="O2" value="36.7" spread="7.4"/>
                    <measurement group_id="O3" value="42" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist Circumference at 16 Weeks</title>
        <description>The circumference measurement was taken in the upright position using a 15-mm width flexible metric tape held close to the body but not tight enough to indent the skin. Waist circumference (WC) was measured in centimeters at the narrowest level midway between the lowest ribs and the iliac crest.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR</title>
            <description>Metformin 2000 mg QD for 16 weeks
Metformin XR: Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks
Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin 5 mg QD for 16 weeks
Saxagliptin: Start 1 pill (5 mg)) for 3 weeks
Remain at 1 pill (5mg dose) for remainder of study</description>
          </group>
          <group group_id="O3">
            <title>Saxagliptin-Metformin XR</title>
            <description>Saxagliptin-Metformin XR (combination pill)
5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks
Saxagliptin-Metformin XR: Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks
Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference at 16 Weeks</title>
          <description>The circumference measurement was taken in the upright position using a 15-mm width flexible metric tape held close to the body but not tight enough to indent the skin. Waist circumference (WC) was measured in centimeters at the narrowest level midway between the lowest ribs and the iliac crest.</description>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109" spread="13"/>
                    <measurement group_id="O2" value="99.6" spread="17"/>
                    <measurement group_id="O3" value="106" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.006</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Menstrual Cycle Interval at 16 Weeks</title>
        <description>The number of menstrual cycles during the previous year was recorded and the average menstrual interval calculated by dividing 365 by the number of menstrual cycles in the previous year . During the study period, the patients in a menstrual diary recorded vaginal bleeding over 16 weeks. The effects of treatment intervention on menstrual cycle interval was calculated evaluated by dividing 112 days by the number of menstrual cycles recorded in each patient’s menstrual cycle diary.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR</title>
            <description>Metformin 2000 mg QD for 16 weeks
Metformin XR: Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks
Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin 5 mg QD for 16 weeks
Saxagliptin: Start 1 pill (5 mg)) for 3 weeks
Remain at 1 pill (5mg dose) for remainder of study</description>
          </group>
          <group group_id="O3">
            <title>Saxagliptin-Metformin XR</title>
            <description>Saxagliptin-Metformin XR (combination pill)
5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks
Saxagliptin-Metformin XR: Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks
Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study</description>
          </group>
        </group_list>
        <measure>
          <title>Menstrual Cycle Interval at 16 Weeks</title>
          <description>The number of menstrual cycles during the previous year was recorded and the average menstrual interval calculated by dividing 365 by the number of menstrual cycles in the previous year . During the study period, the patients in a menstrual diary recorded vaginal bleeding over 16 weeks. The effects of treatment intervention on menstrual cycle interval was calculated evaluated by dividing 112 days by the number of menstrual cycles recorded in each patient’s menstrual cycle diary.</description>
          <units>days between menstrual cycles</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" spread="44"/>
                    <measurement group_id="O2" value="58" spread="29"/>
                    <measurement group_id="O3" value="36" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.026</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglyceride (TRG) /HDL-cholesterol Ratio</title>
        <description>The measure of TRG levels and HDL- cholesterol levels are used as an estimate of insulin sensitivity. A TRG/HDL-C ratio of greater than 3.0 is used as an indirect measure of insulin resistance</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR</title>
            <description>Metformin 2000 mg QD for 16 weeks
Metformin XR: Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks
Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin 5 mg QD for 16 weeks
Saxagliptin: Start 1 pill (5 mg)) for 3 weeks
Remain at 1 pill (5mg dose) for remainder of study</description>
          </group>
          <group group_id="O3">
            <title>Saxagliptin-Metformin XR</title>
            <description>Saxagliptin-Metformin XR (combination pill)
5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks
Saxagliptin-Metformin XR: Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks
Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study</description>
          </group>
        </group_list>
        <measure>
          <title>Triglyceride (TRG) /HDL-cholesterol Ratio</title>
          <description>The measure of TRG levels and HDL- cholesterol levels are used as an estimate of insulin sensitivity. A TRG/HDL-C ratio of greater than 3.0 is used as an indirect measure of insulin resistance</description>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="2.4"/>
                    <measurement group_id="O2" value="2.9" spread="1.3"/>
                    <measurement group_id="O3" value="3.0" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.006</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Free Androgen Index (FAI)</title>
        <description>Hyperandrogenism is measured by a combination of total testosterone (T) and sex hormone binding globulin (SHBG). The FAI was calculated as the quotient 100 x T/SHBG; hyperandrogenism was defined by a FAI value &gt;3.85.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR</title>
            <description>Metformin 2000 mg QD for 16 weeks
Metformin XR: Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks
Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin 5 mg QD for 16 weeks
Saxagliptin: Start 1 pill (5 mg)) for 3 weeks
Remain at 1 pill (5mg dose) for remainder of study</description>
          </group>
          <group group_id="O3">
            <title>Saxagliptin-Metformin XR</title>
            <description>Saxagliptin-Metformin XR (combination pill)
5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks
Saxagliptin-Metformin XR: Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks
Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study</description>
          </group>
        </group_list>
        <measure>
          <title>Free Androgen Index (FAI)</title>
          <description>Hyperandrogenism is measured by a combination of total testosterone (T) and sex hormone binding globulin (SHBG). The FAI was calculated as the quotient 100 x T/SHBG; hyperandrogenism was defined by a FAI value &gt;3.85.</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="2.8"/>
                    <measurement group_id="O2" value="5.5" spread="3.4"/>
                    <measurement group_id="O3" value="4.3" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.006</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With No Clinically Significant Changes in Liver Enzyme Levels or Positive Pregnancy Tests</title>
        <description>The safety criteria will include laboratory values for liver enzymes and document the absence of pregnancy in all participants during the trial</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR</title>
            <description>Metformin 2000 mg QD for 16 weeks
Metformin XR: Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks
Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study</description>
          </group>
          <group group_id="O2">
            <title>Saxagliptin</title>
            <description>Saxagliptin 5 mg QD for 16 weeks
Saxagliptin: Start 1 pill (5 mg)) for 3 weeks
Remain at 1 pill (5mg dose) for remainder of study</description>
          </group>
          <group group_id="O3">
            <title>Saxagliptin-Metformin XR</title>
            <description>Saxagliptin-Metformin XR (combination pill)
5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks
Saxagliptin-Metformin XR: Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks
Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With No Clinically Significant Changes in Liver Enzyme Levels or Positive Pregnancy Tests</title>
          <description>The safety criteria will include laboratory values for liver enzymes and document the absence of pregnancy in all participants during the trial</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>22 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Metformin XR</title>
          <description>Metformin 2000 mg QD for 16 weeks
Metformin XR: Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks
Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study</description>
        </group>
        <group group_id="E2">
          <title>Saxagliptin</title>
          <description>Saxagliptin 5 mg QD for 16 weeks
Saxagliptin: Start 1 pill (5 mg)) for 3 weeks
Remain at 1 pill (5mg dose) for remainder of study</description>
        </group>
        <group group_id="E3">
          <title>Saxagliptin-Metformin XR</title>
          <description>Saxagliptin-Metformin XR (combination pill)
5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks
Saxagliptin-Metformin XR: Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks
Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Common finding with metformin</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study limitations were the small number of patients and the short interval (16 weeks) of drug treatment.
Surrogate measures derived from the OGTT were used to estimate insulin sensitivity and secretion. .</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Karen Elkind-Hirsch</name_or_title>
      <organization>Woman''s Hospital</organization>
      <phone>225-231-5275</phone>
      <email>karen.elkind-hirsch@womans.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

